Loading
Rare cancers are often misdiagnosed, which sends patients down the wrong treatment path. Digital slide sharing could get every case to an expert within days.
Reference pathology review changes the diagnosis in a substantial minority of sarcoma and rare tumour cases, and diagnosis determines treatment entirely. European reference networks and national sarcoma review panels show the model works, but coverage is incomplete and turnaround is slow. Whole-slide imaging plus a funded expert rota plus AI pre-screening for likely rare entities would make it universal.
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Thyroid cancer, Rare and paediatric cancers without markets, Neuroendocrine tumours.
Shares Digital pathology & AI, Histopathology & immunohistochemistry, Rare and paediatric cancers without markets, Neuroendocrine tumours.
Shares Alessandro Gronchi, Histotype-tailored therapy, Sarcomas (soft tissue, bone, GIST).
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares Fragmented care and guideline gaps, Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Rare and paediatric cancers without markets, Sarcomas (soft tissue, bone, GIST).
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).
Shares Rare cancers are not so rare: the rare cancer burden in Europe, Rare and paediatric cancers without markets, Neuroendocrine tumours, Sarcomas (soft tissue, bone, GIST).